The Mounjaro products are pre-filled single-dose pens (2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL), which were approved for commercial sale in May 2022 (NDA 215866) and added to the drug shortage list in December 2022 due to high demand
Given the significant drop from roughly 50% Evernorth client coverage in mid-2025, the trajectory of this coverage trend could serve as an important indicator of how sustainable employer-sponsored GLP-1 weight-loss benefits prove to be industrywide as costs continue straining plan affordability
Other Health Benefits Relevant to Men Several other conditions common in men with obesity often improve with semaglutide treatment
Meals become more satisfying, cravings diminish, and energy levels improve
Each one contributes something different to the overall metabolic effect: GLP-1 Receptor Agonism This is the pathway most people associate with Ozempic